Cory Renauer
Value, research analyst, biotech, small-cap

Anacor's Future Is Positive Despite Tavaborole Issues

There's nothing boring about boron at Anacor Pharmaceuticals (NASDAQ:ANAC). Boron-based compounds have a unique geometry that allows them to have two distinct shapes. Boron's reactivity also allows it to interact with biological targets in unique ways. This means that boron-based drugs have the potential to interact with biological targets in ways that carbon-based compounds can't. At least that's the basis behind all eight of Anacor's clinical stage candidates.

Anacor scientists are experts at synthesizing boron-based compounds that react with their intended targets while minimizing unwanted activity. One of Anacor's targets is the fungal enzyme, leucyl transfer RNA synthetase ((LeuRS)). This enzyme is necessary for protein synthesis in dermatophytes, or the fungi that infect skin, hair, or nails. Let's...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details